Site icon pharmaceutical daily

Pipeline Review on Idiopathic Pulmonary Fibrosis – H2 2020 – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Idiopathic Pulmonary Fibrosis – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis – Pipeline Review, H2 2020, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

The Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 18, 29, 4, 95, 22 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. (Read more…)

Reasons to Buy

  1. Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  2. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  3. Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
  4. Classify potential new clients or partners in the target demographic.
  5. Develop tactical initiatives by understanding the focus areas of leading companies.
  6. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  7. Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  8. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  9. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/5cy6pn

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version